
Loading, please wait...

Loading, please wait...

Familial adenomatous polyposis represents a formidable hereditary cancer predisposition syndrome caused by germline mutations within the adenomatous polyposis coli gene. Patients inevitably develop hundreds to thousands of colorectal adenomas throughout adolescence and early adulthood. Consequently, without prophylactic total colectomy, their lifetime risk of invasive colorectal carcinoma approaches one hundred percent. However, even following extensive prophylactic bowel resection, recurring adenomas frequently emerge in the retained rectal remnant or ileoanal pouch. Therefore, discovering pharmacological agents that suppress adenoma development in FAP remains an urgent global priority.
Gastroenterologists and colorectal surgeons manage rigorous surveillance schedules for these high-risk individuals. Although endoscopic polypectomy removes detected polyps, recurrent lesions impose heavy burdens. Furthermore, surgical interventions carry permanent alterations, such as increased stool frequency and pouch dysfunction. For this reason, medical researchers continue exploring targeted chemoprevention to delay surgery. Currently available medications offer limited efficacy, underscoring the urgent need for novel biological interventions.
Historically, oncologists believed that pre-malignant cells simply proliferated more rapidly than their healthy counterparts. However, recent preclinical work revealed an intriguing biological phenomenon known as super-competition within intestinal stem cell niches. Intestinal stem cells harboring mutations actively secrete inhibitory paracrine factors that suppress surrounding wild-type stem cells. In doing so, these mutant clones monopolize the crypt environment and accelerate tumor initiation.
Consequently, scientists proposed an innovative paradigm: boosting normal tissue fitness to prevent clonal dominance. Preclinical murine models demonstrated that low-dose lithium carbonate restores normal stem cell competitiveness. By activating canonical Wnt signaling in healthy stem cells, lithium prevented competitive suppression by mutant neighbors. As a result, this mechanism arrested clonal expansion and suppressed early adenoma development in FAP models. This remarkable preclinical finding established the mechanistic rationale for human translation in the CHAMP trial.
The CHAMP trial was a prospective, single-arm, phase II clinical investigation conducted at Amsterdam University Medical Center. Investigators recruited eleven evaluable FAP patients aged between 18 and 35 years who possessed intact colons. Importantly, none of the enrolled participants had undergone prior colectomy, ensuring a pristine environment to study natural epithelial biology. In addition, the complete study protocol spanned eighteen months and involved closely monitored therapeutic drug administration.
Participants received daily oral lithium carbonate for six to twelve months, maintaining serum concentrations between 0.2 and 0.4 mmol/L. Meanwhile, clinicians performed serial colonoscopies with biopsies of normal mucosa at baseline, 6, 12, and 18 months. Specifically, the primary endpoint was the change in mutant clone frequency over time. The team traced these clones via NOTUM marker gene expression. Secondary endpoints evaluated macroscopic adenoma burden, safety, and drug tolerability throughout the study.
The trial findings offered definitive answers regarding the clinical utility of low-dose lithium. Across all evaluable participants, researchers observed no significant reduction in mutant clone frequency over time. Statistical analysis demonstrated that clone abundance remained stable across surveillance intervals. Furthermore, endoscopic evaluations revealed no significant decrease in macroscopic adenoma burden. Thus, the trial failed to reproduce the robust chemopreventive efficacy previously observed in mouse models.
From a safety standpoint, oral lithium demonstrated a remarkably favorable and reassuring tolerability profile at the target serum concentrations. Clinicians recorded exclusively mild grade 1 and grade 2 adverse events throughout the treatment phase. Specifically, gastrointestinal symptoms represented the most frequent complaints, with nausea and transient diarrhea occurring in roughly 27 percent of participants. In contrast, no severe systemic toxicities, renal impairments, or neurotoxic events occurred during the trial protocol. Hence, the therapeutic regimen proved safe, even though clinical efficacy endpoints were not met.
Despite the negative primary efficacy outcome, the CHAMP trial achieved a groundbreaking milestone in cancer biology. Specifically, it represents the first human clinical trial to track mutant clone expansion as a therapeutic endpoint. Researchers successfully detected aberrant clones within histologically normal colonic mucosa well before endoscopic lesions appeared. Thus, the investigators proved that clinicians can objectively quantify human stem cell competition and early microenvironmental dynamics.
Moreover, this milestone validates molecular surveillance in hereditary polyposis syndromes. Rather than waiting for visible adenomas, clinicians can detect occult molecular clonal shifts. Therefore, this capability opens promising avenues for future chemoprevention trials. Researchers can now utilize clonal dynamics as an intermediate efficacy biomarker, accelerating early-phase drug screening in clinical oncology.
In Indian clinical practice, hereditary polyposis syndromes present substantial diagnostic and therapeutic challenges due to variable endoscopic access. While lithium carbonate cannot currently be recommended as a chemopreventive tool, the study provides vital clinical clarity. Clinicians must continue to rely on proven therapeutic modalities, including timely endoscopic surveillance and guideline-directed surgery. Additionally, pharmacological options such as sulindac or celecoxib may offer selective benefits in specific postoperative scenarios.
Furthermore, the trial underscores the importance of multidisciplinary care in managing familial colorectal cancer syndromes. Indian gastroenterologists, geneticists, and surgical oncologists should collaborate closely to educate affected families about regular screening. In conclusion, while boosting normal stem cell fitness via lithium did not halt adenoma development in FAP, the trial established a transformative framework for evaluating early cancer interception in humans.
Preclinical studies revealed that APC-mutant intestinal stem cells gain a competitive advantage by secreting factors that suppress surrounding healthy stem cells. Low-dose lithium carbonate activates canonical Wnt signaling within healthy epithelial cells. Consequently, this enhances normal cell fitness and prevents mutant cells from dominating the crypt niche. Researchers designed the CHAMP trial to test whether this mechanism could prevent early polyp formation in human patients.
No, the CHAMP trial did not observe any statistically significant change in mutant clone frequency across the 18-month protocol. Furthermore, serial endoscopic assessments showed no noticeable reduction in macroscopic adenoma burden after six to twelve months of lithium therapy. Nevertheless, the study confirmed that low-dose lithium carbonate was well tolerated by participants, producing only mild, transient gastrointestinal side effects such as nausea and manageable diarrhea.
The trial demonstrates that clinicians cannot currently rely on lithium carbonate to prevent colorectal polyps in patients with familial polyposis. Instead, strict endoscopic surveillance and timely surgical resection remain the cornerstones of standard clinical management. However, the study successfully proved the feasibility of tracing pre-malignant micro-clones in normal-appearing intestinal mucosa. Therefore, this technique establishes an invaluable novel biomarker framework for future oncological chemoprevention research.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Linssen JDG et al. The CHAMP-trial: The CHemopreventive effect of lithium on adenoma development in Familial AdenoMatous Polyposis; a single-arm, phase 2 trial. Clin Transl Gastroenterol. 2026 Nov 19. doi: 10.14309/ctg.0000000000001126. PMID: 43056701.
Linssen JDG, Nijman LE, Vermeulen L, Dekker E. The CHAMP-study: the CHemopreventive effect of lithium in familial AdenoMatous Polyposis; study protocol of a phase II trial. BMC Gastroenterol. 2022;22(1):387.
van Neerven SM, Vermeulen L. Super-competition in colorectal cancer: how mutant stem cells colonize the crypt. Nat Rev Cancer. 2022;22(5):255-267.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The phase 2 CHAMP trial evaluated lithium to curb adenoma development in FAP by boosting normal cell fitness. While lithium was well tolerated and failed to reduce clonal expansion or polyp burden, the trial proved the feasibility of tracing pre-malignant micro-clones in normal human mucosa.
Today

A Bayesian component network meta-analysis of 130 RCTs reveals that self-monitoring and gamification provide the clearest positive effects in mHealth physical activity interventions, while social comparison may have adverse psychological trade-offs.
Today

The GESS-AEEM consensus establishes a clear clinical implementation framework for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder, focusing on transdermal dosing, precise laboratory monitoring, and safety communication.
Today

A multicenter observational study evaluated an 8-week digital health monitoring platform using wearable sensors in ambulatory heart failure. While participants achieved high daily wear-time of 11.7 hours and 80% completion, initial recruitment revealed significant technology-related onboarding barriers.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Yesterday

A clinical decision-support framework using health checkup data from 231,683 adults predicts incident obesity with high discrimination (AUROC 0.918). The system integrates temporal survival analysis and risk-factor explanations to prioritize individualized preventive interventions.
Today